Russia now faced with shortage of anti-HIV drug

18 May 2022

Along with all the other medicines supply problems that the country has recently encountered, Russia is now facing a shortage of anti-HIV drugs, despite a significant increase of their procurements by the state in recent years, reports The Pharma Letter’s local correspondent.

In 2021, the Russian authorities purchased of 391,070 annual courses of HIV therapy (antiretroviral drugs), which covers the country’s need by just over a third (34.4%). That required investments of 31.7 billion roubles ($488 million). According to analysts, these figures should significantly increase this year, however, the government does not have sufficient resources to implement these plans.

According to the data of the Russian Central Research Institute of Epidemiology, currently 1.1 million people live in Russia with a confirmed diagnosis of HIV infection. Under existing state strategy for combatting with HIV, by 2030, the share of patients with HIV receiving antiretroviral therapy should be 95%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Generics